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Abstract
Telomeres are repetitive DNA sequences at linear chromosome termini, protecting chromo-
somes against end-to-end fusion and damage, providing chromosomal stability. Telomeres
shorten with mitotic cellular division, but are maintained in cells with high proliferative capac-
ity by telomerase. Loss-of-function mutations in telomere-maintenance genes are genetic
risk factors for cirrhosis development in humans and murine models. Telomerase deficiency
provokes accelerated telomere shortening and dysfunction, facilitating genomic instability
and oncogenesis. Here we examined whether telomerase mutations and telomere shorten-
ing were associated with hepatocellular carcinoma (HCC) secondary to cirrhosis. Telomere
length of peripheral blood leukocytes was measured by Southern blot and qPCR in 120
patients with HCC associated with cirrhosis and 261 healthy subjects. HCC patients were
screened for telomerase gene variants (in TERT and TERC) by Sanger sequencing. Age-
adjusted telomere length was comparable between HCC patients and healthy subjects by
both Southern blot and qPCR. Four non-synonymous TERT heterozygous variants were
identified in four unrelated patients, resulting in a significantly higher mutation carrier fre-
quency (3.3%) in patients as compared to controls (p = 0.02). Three of the four variants
(T726M, A1062T, and V1090M) were previously observed in patients with other telomere
diseases (severe aplastic anemia, acute myeloid leukemia, and cirrhosis). A novel TERT
variant, A243V, was identified in a 65-year-old male with advanced HCC and cirrhosis sec-
ondary to chronic hepatitis C virus (HCV) and alcohol ingestion, but direct assay measure-
ments in vitro did not detect modulation of telomerase enzymatic activity or processivity. In
summary, constitutional variants resulting in amino acid changes in the telomerase reverse
transcriptase were found in a small proportion of patients with cirrhosis-associated HCC.
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Introduction
Telomeres cap and protect the ends of linear chromosomes from aberrant double-stranded
DNA repair and detrimental end-to-end fusions, as well as ensuring proper genetic partition-
ing into daughter cells. The structure of telomeres is composed of hexanucleotide repeats
bound specifically by ‘shelterin’ proteins [1]. Telomeres function as ‘mitotic clocks’ and
shorten with subsequent mitotic cell divisions. Upon reaching a critically short length, a cellu-
lar signaling cascade involving p53 and p21 arrests cellular replication and induces senescence
[2,3]. The telomerase enzyme complex counterbalances telomere attrition by de novo synthe-
sizing telomere repeats, maintaining telomere length in high proliferative cells.
Telomerase is a ribonucleoprotein and is minimally composed of the catalytic telomerase
reverse transcriptase (TERT) protein and intrinsic RNA component (TERC), which provides
the template for telomere repeat synthesis. The human telomerase holoenzyme is composed of
several accessory proteins, including the dyskerin protein complex [4–6]. Deleterious muta-
tions within telomerase- and telomere-associated genes that impair telomere maintenance
result in ‘telomeropathies’, a spectrum of progressive genetic diseases molecularly caused by
telomere dysfunction and exemplified by dyskeratosis congenita [3,7]. Telomeropathies are
degenerative diseases characterized by premature stem cell senescence, which impart an
increased risk of organ failure for hematopoietic, pulmonary, mucosal, dermal, and hepatic
compartments as well as a predisposition towards the development of cancer. Consistently,
loss-of-function mutations in TERT and TERC genes are related to a spectrum of familial
hepatic disorders [8]. Liver dysfunction in telomeropathy patients is highly variable [9–11].
Mutations within the TERT gene have been found to either directly damage the activity of
the telomerase enzyme, or indirectly decrease the stability of the ribonucleoprotein complex
[12]. Our previous analysis of the prevalence of telomerase mutations in patients with cirrhosis
of diverse etiologic backgrounds—mainly alcohol-, hepatitis B- or C-induced—revealed an
enrichment for TERT gene mutations compared to healthy controls [13]. This indicates that
telomerase dysfunction may predispose to cirrhosis development in response to chronic liver
damage. The persistent and increased cellular turnover from cirrhosis combined with
decreased telomerase function may result in progressive telomere shortening [14] with the
associated chromosomal instability that facilitates the development of cancers, such as hepato-
cellular carcinoma (HCC) [9].
The presence of deleterious telomerase- and telomere-associated gene mutations may serve
as risk factors for cancer development in patients with chronic diseases. In the present work,
we investigated the contribution of telomere dysfunction and genetic mutations in telomerase
components to HCC pathogenesis in cirrhotic patients.
Material and methods
Patient sample collection
Blood samples were collected from a cohort of 261 healthy donors (144/117 male/female) and
120 patients with HCC secondary to hepatic cirrhosis (102/18 male/female) from the Clinical
Hospital, University of São Paulo at Ribeirão Preto Medical School. Patient blood samples
were collected prior to HCC treatment by chemotherapy and/or radiation. Healthy individuals
were recruited from blood donors, as well as healthy child tonsillectomy patients, and healthy
local volunteer study participants. All healthy controls had normal blood cell counts. Healthy
control age ranged from newborn via umbilical cord to 88 years old and HCC patient age ran-
ged from 23 to 85 years old. This study was approved by the Local Ethics Committee (Comitê
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de E´tica em Pesquisa do Hospital das Clı´nicas de Ribeirão Preto– 12050/2011) with written
consent from all participants or their legal guardians (16480/2012).
DNA extraction
Genomic DNA was isolated from white blood cells using the Gentra Puregene Blood kit (Qia-
gen, Maryland, USA), following the manufacturer’s instructions. DNA sample integrity was
analyzed by agarose gel electrophoresis prior to telomere length measurements and gene
sequencing.
Telomere length analysis
For terminal restriction fragment (TRF), the analysis was performed as previously described
[15] with the TeloTAGGG Telomere Length Assay (Roche Applied Science, Mannheim, Ger-
many). Briefly, 800 ng genomic DNA was digested by FastDigest HinfI and RsaI (Thermo Sci-
entific, Waltham, MA, USA) at 37˚C for 2 h. Following digestion, DNA fragments were
electrophoresed for 5 h on a 0.8% agarose gel, denatured, neutralized, and transferred to a
nylon membrane for Southern blot analysis with proprietary digoxigenin (DIG)-labeled
probes and chemiluminescent substrates. We determined the mean TRF length based on the
equation S(ODi)/S(ODi/Li), where ODi represents the chemiluminescent signal and Li corre-
sponds to the fragment length at a given position. For each experiment, a reference sample was
included.
Relative telomere length was measured by qPCR as previously described [15]. The qPCR
was performed in triplicate with each 24 μL reaction comprising of 1.6 ng genomic DNA, 1×
Rotor-Gene SYBR Green (manufacturer), 1× PCR Master Mix (Qiagen, Hilden, Germany),
and primers: for telomere amplification, 300 nM forward (5’-CGGTTTGTTTGGGTTTGGGTT
TGGGTTTGGGTTTGGGTT-3’)and reverse (5’-GGCTTGCCTTACCCTTACCCTTACCCTTA
CCCTTACCCT-3’), or for the single gene 36B4 300 nM forward (5’-CAGCAAGTGGGAAGG
TGTAATCC-3’) and 500 nM reverse (5’ CCCATTCTATCATCAACGGGTACAA 3’). All qPCR
reactions were prepared on a QIAgility automated pipettor (Qiagen, California, USA), and
amplified in a Rotor-Gene Q (Qiagen) real-time PCR cycler as follows: 5 min at 95˚C, and
either 25 cycles of 7 s at 98˚C and 10 s at 60˚C (telomere), or 35 cycles of 7 s at 98˚C and 10 s at
58˚C (single gene). To determine the telomere length for each sample, we used the telomere to
single copy gene (T/S) ratio based on the ΔCt (Cttelomere/Ctsingle gene). The T/S ratio for a given
sample (x) was normalized to the mean T/S ratio of a reference sample (2–(ΔCtx−ΔCtr) = 2−ΔΔCt).
Each qPCR run included samples for the standard curve and two reference reactions. All sam-
ple data included had reference samples with less than 95% variation. Linear regressions to
correlate telomere length measurements by TRF and qPCR were performed using R software
(v3.0.3) and Prism v5 (GraphPad Software Inc, CA, USA).
Mutation screening
TERT and TERC genes were screened for genetic variants as previously described [16]. Non-
synonymous mutations (missense, nonsense, and frameshift) and mutations with an allele fre-
quency<1% were included in this work. PCR conditions are listed in S1 Table. In silico predic-
tion of the possible impact of non-synonymous variants on the structure and function of the
human TERT enzyme was performed by PolyPhen-2 [17] and SIFT [18] tools. The variants
were annotated using the Combined Annotation Dependent Depletion (CADD, http://cadd.
gs.washington.edu/home). From this annotation, we provided the ‘CADD score’ of each vari-
ant, which corresponds to the PHRED-like scaled C score [19], a predictor of deleteriousness.
We considered variants with CADD scores higher than 10 as potentially pathogenic.
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Telomerase repeat amplification protocol
Wild-type and variant telomerase were reconstituted in vivo in telomerase-negative WI 38
VA13 ALT-positive cells (ATCC) by transient transfection with 2 μg puc57-TERC, 2 μg
pcDNA3-Flag-hTERT and Superfect Transfection Reagent (Qiagen), following the manufac-
turer’s instructions. Cell lysates were prepared with CHAPS buffer (TRAPeze XL Telomerase
Detection Kit, Millipore), clarified by centrifugation, and protein concentration determined
by Pierce BCA Protein Assay (Thermo Scientific). Reconstituted telomerase in cell lysate con-
taining 300 ng of total protein was analyzed by the PCR-based Telomeric Repeat Amplification
Protocol (TRAP) assay with the TRAPeze XL Telomerase Detection kit (Millipore), following
the manufacturer’s instructions. TRAP reactions were electrophoresed on non-denaturing
10% polyacrylamide gel and stained with ethidium bromide. Telomerase activity was deter-
mined by measuring the total intensity of products on the gel using an ImageQuant imaging
system and software (GE Healthcare Life Sciences). Quantification was based on TRAP assays
using cell lysates from two independent transfections.
Telomerase activity and processivity assay
Wild-type and variant telomerase were reconstituted in vivo in telomerase-positive
HEK293FT cells (Invitrogen, Carlsbad, CA) by transient transfection with pcDNA-Flag-
hTERT and pBS-U1-hTR [20]. The catalytically inactive negative control D868N mutant was
appended with a 3×Flag tag in place of a single Flag in the pcDNA-Flag-hTERT vector. The
reconstituted telomerase was then immuno-purified from cell lysates and analyzed by the
direct primer-extension assay at physiological nucleotide concentrations, as previously vali-
dated and described [20–22]. The 10 μL direct primer-extension reaction contained 5 μM
dTTP, 5 μM dATP, 5 μM dGTP, 0.165 μM α-32P-dGTP (3000 Ci/mmol, 10 mCi/ml, Perkin-
Elmer), and 1 μM (TTAGGG)3 DNA primer in 1× reaction buffer (0.5 mM MgCl2, 50 mM
Tris-HCl pH 8.3, 2 mM DTT, and 1 mM spermidine). In transfected HEK293FT cells, wild-
type and variant telomerase expression was confirmed by Western blot for the Flag-tagged
TERT protein with GAPDH as an internal control [23]. Telomerase activity was determined
by measuring the total intensity of telomerase-generated products on the gel and normalized
against the TERC level determined by Northern blot for TERC extracted from immuno-puri-
fied telomerase. Telomerase processivity was determined by the equation—ln2/(2.303×k), with
k as the slope of the log plot of the intensity of the telomerase-generated major bands divided
by the number of radioactive dGTP incorporations [24]. Quantification was based on four
direct activity assays using cell lysates from two independent transfections.
Results
We assessed the telomere lengths of peripheral blood leukocytes of patients with HCC and cir-
rhosis. Telomere length was measured by qPCR in 261 healthy subjects with no history of liver
disease or malignant formation and in 120 patients with HCC associated with cirrhosis (Fig
1A; Table 1). Cirrhosis was mainly caused by hepatitis B- or C-virus alone (11% and 29%,
respectively), alcohol (17.5%), or a combination of virus infection and alcohol (32.5%). This
study classified 60 patients (50%) as Child-Pugh class A, 38 (32%) as Child-Pugh class B, and
18 (15%) as Child-Pugh Class C.
Telomere length was not statistically different between HCC patients and healthy subjects
(p = 0.6), with a similar loss of telomere length with age in both groups (p = 0.0001) (Fig 1A).
In order to validate qPCR results, we used Southern blot, the gold standard technique for telo-
mere length, which was performed on 204 healthy subjects and 48 HCC patients, all randomly
selected. Again, no significant difference in telomere length was detected between patients and
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healthy subjects (p = 0.9), and both HCC patients and healthy subjects showed significant telo-
mere shortening according to age (p = 0.0001), with a mean loss of 73 and 48 base pairs (bp)
per year, respectively, but there was no significant difference between the two groups (p = 0.2)
(S1A Fig). Eighteen out of the 120 (15%) HCC patients tested were female and 102 (85%) were
male. Median of telomere length was higher in females than in males when analyzed by qPCR
(p = 0.01) (Fig 1B) and a concordant tendency for increased telomere length in women was
observed by Southern blot (p = 0.07) (S1B Fig).
Sequencing of the TERT gene from 120 HCC patients revealed four non-synonymous
TERT heterozygous variants: A243V, T726M, A1062T, and V1090M from four unrelated
patients (Fig 2A, Table 2), demonstrating a significantly higher mutation carrier frequency in
HCC patients (3.3%) as compared to 198 healthy subjects (p = 0.02, by Fisher’s exact test) pre-
viously screened for TERT gene variants in Calado et al. [25]. Synonymous and intronic vari-
ants identified in our cohort are provided in S2 Table. No TERC variants were detected in
HCC patients.
For the control sample size in our previous study (n = 528), the statistical power to identify
a single-nucleotide polymorphism (SNP) with a minor allele frequency of 1% would be
approximately 90% [13]. Specifically for the TERT A1062T variant, we previously screened
2,000 healthy controls and found an allele frequency of 0.007 [13]. Herein aggregate data were
accessed from the Exome Aggregation Consortium (ExAC) of more than 100,000 sequenced
alleles, and 190 missense variants in TERT were found, significantly below the 469 missense
variants expected, indicating that the gene is highly conserved in humans.
Three of the four missense TERT gene mutations, T726M, A1062T, and V1090M, within
our sample cohort were previously described by Liang et al. [26], Calado et al. [13], Calado
et al. [25], and Yamaguchi et al. [16], in patients with other telomere diseases: severe aplastic
anemia, acute myeloid leukemia, and cirrhosis. T726M was observed in 6 out of 121,390 alleles,
of which one was from African and one was from European (non-Finnish) populations
(minor allele frequency of 5×10−5) in ExAC. This variant has been previously described in one
patient with aplastic anemia and in her asymptomatic father [26], as well as in 2 out of 209
Fig 1. Distribution of age-matched telomere length in healthy subjects and HCC patients by qPCR. (A) Telomere length analysis revealed no
statistical differences between HCC patients and healthy subjects analyzed by qPCR. Patients and controls were age-matched: Slope: −0.007882
±0.0007139; y-intercept when x = 0: 1.080±0.02516). (B) Telomere length was longer in females than in males (**p = 0.01).
https://doi.org/10.1371/journal.pone.0183287.g001
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Table 1. Demographic and clinical characteristics of cirrhotic patients with hepatocellular carcinoma.
Frequency Percentage p value
Telomere length classification* 0.01
<p25% 29 24
p25 –p50 31 26
p50 –p75 30 25
>p75% 30 25
Age (years) 0.1
Female (39–79)
Male (28–85)
Median (<p50%: 59; >p50%: 58.5)
Gender <0.01
Female 18 15
Male 102 85
Primary disease
NASH 1 1
Cirrhosis 116 97
Hepatitis 3 2
Etiology >0.05
Hepatitis B virus 13 11
Hepatitis C virus 35 29
Alcoholism 21 17.5
Virus (B or C) + Alcoholism 39 32.5
Cryptogenic 7 6
NASH 4 3
HH 1 1
CHILD 0.6
A 60 50
B 38 32
C 18 15
ND 4 3
MELD 0.4
<10 28 23
10–19 80 67
20–29 6 5
ND 6 5
Tumor presentation
Diffuse infiltrative 16 13
Multinodular 28 23
Uninodular 75 63
ND 1 1
Milan criteria
No 54 45
Yes 66 55
Metastasis
Adrenal 1 1
Lung 2 2
Bone 5 4
No research 8 7
(Continued )
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smokers with emphysema [22]. A1062T was found in 1,496 out of 113,542 alleles with 13
homozygotes (minor allele frequency of 1×10−2), mostly from European populations. In the
Latin American population, this variant was found in 33 out of 10,973 alleles (minor allele fre-
quency of 3×10−3) in ExAC. A1062T has been previously described in healthy individuals, but
its frequency increases in patients with aplastic anemia [16], acute myeloid leukemia [25], and
cirrhosis [13]. V1090M was observed in 7 out of 119,373 alleles (3 in African, 3 in Latin Ameri-
can and 1 in European populations; allele frequency of 6×10−5) in ExAC. This variant has been
previously described as pathogenic in patients with severe aplastic anemia [16]. We found this
variant just as deleterious by SIFT, and was predicted to be among the 1% most deleterious
substitutions by CADD (score = 21); PolyPhen has categorized this variant as ‘benign’ (Fig
2A), which indicates that in silico predictions are useful, but insufficient to recapitulate the
functional impact in vivo.
The A243V variant described here has not been previously reported in ExAC. This novel
heterozygous TERT variant was identified in a 65-year-old male with advanced HCC and cir-
rhosis secondary to chronic hepatitis C infection and alcohol ingestion (Table 2). In silico pre-
diction of possible impact of this amino acid substitution on the structure and function of the
human TERT enzyme was performed, demonstrating a putative benign impact on telomerase
activity (CADD score = 0.03; Fig 2A). To confirm the in silico prediction, two in vitro assays
were performed: PCR-based TRAP and direct assay (Fig 2B–2F). The relative intensity of telo-
meric DNA repeats quantitated from the TRAP gel showed little to no modulation in telome-
rase activity for this variant, as well as for the other three variants, compared to the wild-type
telomerase (Fig 2B and 2C). A direct primer extension assay was performed for the TERT
A243V and T726M variants (Fig 2D). The catalytically inactive D868N mutant, which lacks
one of the three essential aspartic acids, was included as control, along with the wild-type
TERT without TERC. These mutant telomerases were immuno-purified from HEK293FT cell
lysates for activity and processivity analysis. The TERT T726M mutant displayed decreased
activity, consistent with previous reports [22,25]. Conversely, the direct assay showed a minor
increase in activity and processivity of the novel A243V variant compared to the wild-type
enzyme, suggesting that the amino acid substitution had little impact on TERT enzymatic
function (Fig 2D and 2F). The A243V variant did not affect TERT protein expression or telo-
merase ribonucleoprotein formation, evidenced by similar levels of TERT in cell lysates and
co-immunoprecipitated TERC (Fig 2E).
Table 1. (Continued)
Frequency Percentage p value
No 104 86
BCLC 0.8
A1 7 6
A2 12 10
A3 14 12
A4 19 16
B 28 23
C 22 18
D 18 15
* T/S ratio; p = percentile
NASH: non-alcoholic steatohepatites; HH: Hereditary hemochromatosis; CHILD: Child-Pugh score; MELD: Model for End-Stage Liver Disease; BCLC:
Barcelona-Clinic Liver Cancer; ND: follow up lost.
https://doi.org/10.1371/journal.pone.0183287.t001
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Fig 2. The functional consequences of variants on enzyme activity. (A) Four non-synonymous TERT heterozygous mutations (A243V, T726M,
A1062T, and V1090M) were detected in HCC patients in both forward and reverse sequences; in silico analysis was performed by CADD, PolyPhen,
and SIFT to predict the impact of each variant on the structure and function of the enzyme. The telomerase enzyme is represented in its three domains:
N-terminal (green), Reverse Transcriptase (blue), and C-terminal (orange) with all described mutations in red (adapted from http://telomerase.asu.edu/
diseases.html#tert). (B) Analysis of TERT variants’ impact on telomerase activity using PCR-based TRAP assay: representative gel image of telomeric
DNA repeats generated from wild-type (WT) and variant telomerases reconstituted in vivo. The cell lysates for TRAP assay were obtained from
reconstitution of the WT, empty, or mutated TERT expression vectors in the telomerase-negative VA13 cell line cotransfected with TERC-containing
vector. No telomeric DNA repeats were obtained from lysates of VA13 cells and cells transfected with the empty vector (negative controls). (C) Mean
intensity (and standard error) of telomeric DNA repeats quantitated from the TRAP gels. Intensities are shown relative to the WT (set as 100%). Cell
Telomerase mutation and hepatocellular carcinoma
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Telomere length was performed on the patients carrying the TERT variants and no signifi-
cant difference between patients and healthy controls was observed either by qPCR (p = 0.7)
or Southern blot (p = 0.1) (Fig 3A and 3B, respectively). Linear regression was used to estimate
the correlation between qPCR and Southern blot, resulting in r2 = 0.6, r2 = 0.4, and r2 = 0.9 in
controls (n = 76), HCC patients (n = 51), and TERT-mutant HCC patients (n = 4), respectively
(S2 Fig). Loss of 48 bp/year by TRF was found in control group. Both techniques showed high
proximity values, ensuring the reliability of telomere length measurement.
lysates were obtained from two independent transfections. The TRAP assay was performed for each transfection. (D) Analysis of TERT variants’
impact on telomerase activity and processivity using direct assay: gel image of telomeric DNA repeats generated from WT and variant telomerases
reconstituted in vivo and immuno-purified. The decreased total intensity of the DNA repeat products generated by variant telomerases relative to wild-
type enzyme reflects slightly impaired enzymatic activity of TERT T726M. Processivity remained similar to WT for the two variants tested (A243V and
T726M). The TERT mutation D868N is a negative control, catalytically defective in one of the three essential aspartic acid residues for reverse
transcription. (E) Northern blot for TERC levels from immuno-purified telomerases and Western blot for TERT expression levels in cells. Western blot
performed with anti-Flag and anti-GAPDH antibodies for ectopically expressed Flag-tagged TERT and endogenous GAPDH, respectively. The greater
intensity of the catalytically inactive D868N mutant was due to the presence of a 3×Flag tag in place of a single Flag present for the WT and variant
TERT proteins. (F) Mean telomerase activity and processivity derived from four independent activity assays. Enzymes were purified from cell lysates
from two separate transfections.
https://doi.org/10.1371/journal.pone.0183287.g002
Table 2. Clinical data and etiology of cirrhosis in four HCC patients harboring TERT mutations.
ID Age (yrs) Stage Exon Mutation Etiology Follow up
#1 HCC 65 Okuda III, BCLC D 2 A243V HCV+EtOH Tx; death not related to HCC
#2 HCC 66 Okuda I, BCLC A1 6 T726M EtOH Tx; No recurrent HCC
#3 HCC 47 Okuda III, BCLC D 15 A1062T HBV None
#4 HCC 56 Okuda I, BCLC A1 15 V1090M HBV Tx; death not related to HCC
ID: patient identification; HCC: hepatocellular carcinoma; BCLC: Barcelona-Clinic Liver Cancer; HBV: hepatitis B virus; HCV: hepatitis C virus; EtOH:
alcoholism; Tx: liver transplant; None: follow up discontinued.
https://doi.org/10.1371/journal.pone.0183287.t002
Fig 3. Distribution of age-matched telomere length in healthy subjects and HCC mutated patients. Healthy subjects (n = 261) are represented
as grey circles; patients carrying TERT variants (n = 4) are represented as colored circles. Telomere length given as (A) T/S ratio by qPCR (B) and
kilobases (kb) by Southern blot.
https://doi.org/10.1371/journal.pone.0183287.g003
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Discussion
In the present study, we found that constitutional TERT missense variants were found in 3.3%
of patients diagnosed with HCC associated with cirrhosis, but peripheral blood leukocyte telo-
mere length did not correlate with HCC development. A previous study reported on one case
of HCC in a patient with cirrhosis associated with non-alcoholic fatty liver carrying a TERT
mutation [27].
Three out of the four variants that we have found in our HCC cohort were previously asso-
ciated with telomeropathies in other studies [13,16,25,26]. The T726M TERT variant was
observed in a Japanese patient with very severe aplastic anemia. The patient, a 9-year-old girl,
presented very short telomeres whereas her father, also carrying the mutation, was asymptom-
atic and presented normal telomere length, suggesting disease anticipation [26]. The A1062T
variant was described by Yamaguchi et al. [16]. Subsequently, Calado et al. [25] described
A1062T with an allele frequency 3-fold enriched in patients with acute myeloid leukemia. The
A1062T variant was also found in higher frequency in cirrhotic patients [13]. The V1090M
variant, located in the C-terminal of TERT, was described in a 64-year-old Hispanic patient
with severe aplastic anemia and short telomeres (allele frequency of 0.005) [16]. The PCR-
based TRAP assay was previously performed for these three TERT variants (revised by Zaug
et al. [28]). Xin et al. [29] reconstituted the T726M variant in vivo and reported no significant
modulation in telomerase activity, in agreement with our findings. The A1062T variant was
reconstituted in VA13 cells in a previous study [25] and the telomerase activity was 60% com-
pared to the wild-type. Here we found reduced telomeric DNA repeat intensity in TRAP for
this variant when compared to wild-type (80%). Yamaguchi et al. showed that in patient’s
peripheral-blood mononuclear cells the V1090M variant displayed approximately 50% activity
when compared with unrelated controls. In vitro this variant exhibited less than 1% activity
[16]. In contrast, we have detected a slightly reduced activity of this variant in our TRAP assay
(80% activity of the wild-type), although our in silico prediction partially agreed with previous
studies.
A novel variant (A243V) was also found, located at N-terminal region of TERT. Mutations
in this region usually modify the enzymatic processivity, correlating with shorter telomeres in
cells [30,31]. However, in the present work, the patient carrying this variant had telomere
lengths in the normal range and the A243V substitution did not appear to modulate telome-
rase ability to elongate telomeres both in silico and in vitro.
Zaug et al. [28] have comprehensively analyzed the effects of telomere disease-associated
TERT variants on telomerase enzymatic activity and processivity through direct assay. The
direct enzyme assay assesses the ability of telomerase to elongate telomeres without PCR
amplification, as performed in the TRAP assay, avoiding potential artifacts. In their work,
three of the four TERT variants we describe here were tested and they found that TERT
T726M and V1090M did not significantly change processivity, whereas A1062T tended to
reduce processivity. Although they did not test A243V, other variants in the same region
(DAT, in the TEN domain) were tested and did not modulate processivity, but they observed
dissociation between in vivo and in vitro activities of telomerase in this region. The authors
postulate that whereas some mutations clearly abolish telomerase enzymatic activity, it is pos-
sible that small reductions in telomerase function are sufficient to shorten telomeres over
many years. They also suggest that, alternatively, mutations may interfere with other telome-
rase functions, such as its recruitment to telomeres or other proteins, which are necessary in
vivo but not easily revealed in vitro [28]. The TERT variants that were observed in our cohort
may be responsible for disturbing telomerase homeostasis in vivo, but we were not able to
detect this phenomenon in our in vitro assays.
Telomerase mutation and hepatocellular carcinoma
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In conclusion, our observations indicate that TERT variants are observed in a small number
of patients with HCC associated with cirrhosis.
Supporting information
S1 Fig. Distribution of age-matched telomere length in healthy subjects and HCC patients
by Southern blot. (A) Telomere length analysis revealed no statistical differences between
HCC patients and healthy subjects as analyzed by Southern blot. (B) Telomere length by
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line represents the data best fit (r2 = 0.5); (B) Telomere length from 49 HCC patients. Linear
regression plots of qPCR (T/S ratio) × TRF analysis (kb) measurements; solid line represents
the data best fit (r2 = 0.4); (C) Telomere length from HCC mutated patients. Linear regression
plots of qPCR (T/S ratio) × TRF analysis (kb) measurements; solid line represents the data best
fit (r2 = 0.9).
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